FDA Permits Resumption Of BioNTech/MediLink Therapeutics Partnered Section 1 Research For Most cancers Drug With Decrease Dose – BioNTech (NASDAQ:BNTX)

The FDA has lifted the partial scientific maintain on MediLink Therapeutics’ Section 1 trial for BNT326/YL202,…